Evolus (NASDAQ:EOLS) Price Target Raised to $25.00

Evolus (NASDAQ:EOLS) had its price target increased by Barclays from $22.00 to $25.00 in a research report released on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

EOLS has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Tuesday, January 21st.

Evolus Trading Up 0.6 %

Shares of NASDAQ:EOLS opened at $13.58 on Wednesday. The stock has a 50 day moving average of $12.90 and a 200 day moving average of $14.08. The company has a market cap of $859.90 million, a PE ratio of -14.92 and a beta of 1.33. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. KBC Group NV purchased a new position in Evolus in the 4th quarter worth approximately $49,000. IFP Advisors Inc raised its holdings in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Evolus during the 4th quarter worth approximately $106,000. Rafferty Asset Management LLC purchased a new stake in shares of Evolus during the 4th quarter worth approximately $115,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Evolus during the 4th quarter worth approximately $118,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.